Verici Dx plc VRCDF
Set alert
At close · Oct 29
- YTD
- 0.00%
- 1 year
- -60.53%
- Open
- 2.91
- Prev close
- 0.003
- Mkt cap
- 11.91M
- Vol
- 200
- Avg vol
- 0
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 2.91
- High
- 2.91
News
9 hours ago seekingalpha.com
Verici Dx plc (VRCDF) Shareholder/Analyst Call Transcript
Verici Dx plc (VRCDF) Shareholder/Analyst Call Transcript
2 months ago proactiveinvestors.co.uk
Verici Dx gains Olink Certified Service Provider status to expand proteomics offering
Verici Dx PLC (AIM:VRCI) has become an Olink Certified Service Provider, allowing the transplant diagnostics company to offer Olink-based proteomics assay services from its CAP-certified and…
4 months ago businesswire.com
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from…
4 months ago businesswire.com
Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that collaborators will present new data on the predictive…
5 months ago businesswire.com
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
FRANKLIN, Tenn.--(BUSINESS WIRE)--In the first and last paragraphs, the text should read: Pre-Transplant Risk Assessment (instead of: Pre-Transplant Rejection Assessment). The updated release reads:…
5 months ago businesswire.com
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation…
11 months ago proactiveinvestors.co.uk
Verici Dx rises after passing key US laboratory accreditation audit
Verici Dx PLC (AIM:VRCI) shares were up as much as 11% in early trading after the diagnostics company announced it had successfully completed its second biennial inspection by the College of American…
11 months ago proactiveinvestors.co.uk
Verici Dx climbs on 'preferred provider' deal with US healthcare network
Verici Dx PLC (AIM:VRCI) shares skipped 12% higher to 0.7p after the developer of diagnostic tests for organ transplants bagged a new agreement with a healthcare network in the United States. The…
1 year ago seekingalpha.com
Verici Dx plc - Special Call
Verici Dx plc - Special Call Company Participants Sara Barrington - CEO & Executive Director David Anderson - CFO & Company Secretary Presentation Operator Good morning, and welcome to the Verici Dx…
1 year ago proactiveinvestors.co.uk
Verici Dx shares jump 23% as transplant test rollout gathers pace
Shares in Verici Dx PLC (AIM:VRCI) surged 23% in early trading on Monday after the diagnostics company reported encouraging progress in the commercial rollout of its Tutivia test for kidney…
1 year ago proactiveinvestors.co.uk
Verici Dx plans fresh funding round to boost US test rollout
Verici Dx PLC (AIM:VRCI) is preparing to raise new equity funding as it looks to ramp up the commercial rollout of its flagship transplant diagnostic, Tutivia, in the US following a key Medicare…
1 year ago proactiveinvestors.co.uk
Verici Dx soars as Tutivia tests are confirmed by Medicare
Verici Dx PLC (AIM:VRCI) shares soared in Thursday morning's trade as the med-tech firm confirmed it had secured Medicare coverage for its Tutivia assay product. It comes as a technical assessment…
1 year ago proactiveinvestors.co.uk
Verici Dx says its seen a significant increase in Tutivia orders
Verici Dx PLC (AIM:VRCI) told investors it has seen a significant increase in Tutivia test orders during the first quarter. The company, which has an RNA-based test used by patients before kidney…
1 year ago businesswire.com
FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians
CORALVILLE, Iowa--(BUSINESS WIRE)--FBB Biomed today announced it has signed a Master Services Agreement with Verici Dx plc (AIM: VRCI.L), for Laboratory Services for Research-Use-Only (RUO) (FDA…